Citations

Clear

6274 citation(s) found for "To, Andrew".

Recommendations for effective documentation in regional anesthesia: an expert panel Delphi consensus project
Lotfy, Ahmed , Atterton, B, Crowe, G, Barratta, Jaime L, Johnson, Mark , Viscusi, Eugene R. , Adhikary, Sanjib Das , Albrecht, Éric , Boretsky, Karen , Boublik, Jan , Breslin, Dara S., Ch’ng, Alan Swee Hock , Chuan, Alwin , Conroy, Patrick , Daniel, Craig O. , Daszkiewicz, Andrzej , Delbos, Alain, Dîrzu, Dan Sebastian , Dmytrіiev, Dmytro , Fennessy, Paul , Frizelle, Henry P., Gadsden, Jeff, Gautier, Philippe , Hardman, H. David , Harrop‐Griffiths, W., Hebbard, Peter , Hernandez, Nadia , Hlásny, Jakub , Iohom, Gabriella , Kalagara, Hari , Kinirons, B., Leng, Jody C. , Lim, Yean Chin , Lobo, Clara , Ludwin, Danielle, Macfarlane, Alan , Machi, Anthony , Mahon, Padraig, Mannion, Stephen , McLeod, David H., Merjavy, Peter , Miščuks, Aleksejs , Mitchell, Christopher H. , Μoka, Εleni , Moran, Peter, Ngui, Ann, Nin, Olga C. , OʼDonnell, Brian D. , Pawa, Amit , Perlas, Anahi , Pozek, John-Paul J., Rebelo, Humberto C, Roqués, V, Schroeder, Kristopher M. , Schwartz, Gary , Shorten, George , Stevens, Markus F. , Turbitt, Lloyd , Valdés-Vilches, Luis Fernando , Webster, Katrina, Wolmarans, Morné , Woodworth, Glenn E. , Worek, Andrew K, Moran, EML , Ahmed, Hassan M , Viscusi, Eugene , Adhikary, Sanjib , Byrne, Kelly , Chuan, Alwin , Dirzu, Dan Sebastian , Dmytriiev, Dmytro , Gupta, Rajnish K , Ip, Vivian H Y , Jeng, Christina L , Johnson, Rebecca L , Lim, Yean Chin , Macfarlane, Alan James Robert , Machi, Anthony T , Merjavy, Peter , Pawa, Amit , Perlas, Anahi , Porter, Steven B , Schwenk, Eric S , Sermeus, Luc , Srinivasan, Karthikeyan , Theodoraki, Kassiani , Volk, Thomas , Wilson, Sylvia H , Woodworth, Glenn , Moran, E M Louise , Kalagara, Hari , Lobo, Clara , Moka, Eleni , Albrecht, Eric , Crowe, Gillian-Genevieve , Ch'ng, Alan, Fischer, H. B. J. , Gupta, Rajnish K. , Gürkan, Yavuz , Ip, Vivian , Johnson, Rebecca L. , Lansdown, Andrew Kenneth, Porter, Steven B. , Schwenk, Eric S. , Volk, Thomas , Webster, Katrina, Wiesmann, Thomas

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 22, 2022 | Volume: 47 | Issue: 5 | Pages: 301-308

10.1136/rapm-2021-103136 | PMID 35193970 Get It

Background and objectives Documentation is important for quality improvement, education, and research. There is currently a lack of recommendations regarding key aspects of documentation in regional anesthesia. The aim of this study was to establish recommendations for documentation in regional anesthesia. Methods Following the formation of the executive committee and a directed literature review, a long list of potential documentation components was created. A modified Delphi process was then employed to achieve consensus amongst a group of international experts in regional anesthesia. This consisted of 2 rounds of anonymous electronic voting and a final virtual round table discussion with live polling on items not yet excluded or accepted from previous rounds. Progression or exclusion of potential components through the rounds was based on the achievement of strong consensus. Strong consensus was defined as ≥75% agreement and weak consensus as 50%–74% agreement. Results Seventy-seven collaborators participated in both rounds 1 and 2, while 50 collaborators took part in round 3. In total, experts voted on 83 items and achieved a strong consensus on 51 items, weak consensus on 3 and rejected 29. Conclusion By means of a modified Delphi process, we have established expert consensus on documentation in regional anesthesia.
Association of hypothyroidism with outcomes in hospitalized adults with COVID‐19: Results from the International SCCM Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID‐19 Registry
Bogojevic, Marija , Bansal, Vikas , Pattan, Vishwanath , Tekin, Aysun , Sharma, Mayank , Nou, Abigail T. La, Hanson, Andrew C. , Schulte, Phillip J. , Qamar, Shahraz , Morales, Diana J. Valencia , Perkins, Nicholas , Kaufman, Margit, Melamed, Roman , Christie, Amy B. , Tarabichi, Yasir , Heavner, Smith F. , Kumar, Vishakha K. , Bhagra, Sumit , Lal, Amos , Domecq, Juan Pablo , Group, Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID‐19 Registry Investigator, Koritala, Thoyaja , Asghar, Muhammad Sohaib , Singh, Romil , La Nou, Abigail T, Zec, Simon , Valencia Morales, Diana J , Denson, Joshua L , Gajic, Ognjen , Kashyap, Rahul , Lal, Amos , Domecq, Juan Pablo , Bansal, Vikas , Asghar, Muhammad S , Tekin, Aysun , Domecq Graces, Juan Pablo , Nou, Abigail La, LeMahieu, Allison , Deo, Neha , Denson, Joshua L. , Banner‐Goodspeed, Valerie , Walkey, Allan J. , Gajic, Ognjen , Kashyap, Rahul , Group, Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID‐19 Registry Investigator

Mayo Clinic

Clinical Endocrinology | February 18, 2022 | Volume: 101 | Issue: 1 | Pages: 85-93

10.1111/cen.14699 | PMID 35180316 Get It

AbstractIntroductionCoronavirus disease 2019 (COVID‐19) is associated with high rates of morbidity and mortality. Primary hypothyroidism is a common comorbid condition, but little is known about its association with COVID‐19 severity and outcomes. This study aims to identify the frequency of hypothyroidism in hospitalized patients with COVID‐19 as well as describe the differences in outcomes between patients with and without pre‐existing hypothyroidism using an observational, multinational registry.MethodsIn an observational cohort study we enrolled patients 18 years or older, with laboratory‐confirmed severe acute respiratory syndrome coronavirus‐2 infection between March 2020 and February 2021. The primary outcomes were (1) the disease severity defined as per the World Health Organization Scale for Clinical Improvement, which is an ordinal outcome corresponding with the highest severity level recorded during a patient's index COVID‐19 hospitalization, (2) in‐hospital mortality and (3) hospital‐free days. Secondary outcomes were the rate of intensive care unit (ICU) admission and ICU mortality.ResultsAmong the 20,366 adult patients included in the study, pre‐existing hypothyroidism was identified in 1616 (7.9%). The median age for the Hypothyroidism group was 70 (interquartile range: 59–80) years, and 65% were female and 67% were White. The most common comorbidities were hypertension (68%), diabetes (42%), dyslipidemia (37%) and obesity (28%). After adjusting for age, body mass index, sex, admission date in the quarter year since March 2020, race, smoking history and other comorbid conditions (coronary artery disease, hypertension, diabetes and dyslipidemia), pre‐existing hypothyroidism was not associated with higher odds of severe disease using the World Health Organization disease severity index (odds ratio [OR]: 1.02; 95% confidence interval [CI]: 0.92, 1.13; p = .69), in‐hospital mortality (OR: 1.03; 95% CI: 0.92, 1.15; p = .58) or differences in hospital‐free days (estimated difference 0.01 days; 95% CI: −0.45, 0.47; p = .97). Pre‐existing hypothyroidism was not associated with ICU admission or ICU mortality in unadjusted as well as in adjusted analysis.ConclusionsIn an international registry, hypothyroidism was identified in around 1 of every 12 adult hospitalized patients with COVID‐19. Pre‐existing hypothyroidism in hospitalized patients with COVID‐19 was not associated with higher disease severity or increased risk of mortality or ICU admissions. However, more research on the possible effects of COVID‐19 on the thyroid gland and its function is needed in the future.
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach
Arber, Daniel A. , Hasserjian, Robert P. , Mathews, Vikram , Roberts, Andrew W. , Schiffer, Charles A. , Roug, Anne Stidsholt , Tefferi, Ayalew , Mathews, Vikram , Tefferi, Ayalew , Roberts, Andrew W , Arber, Daniel A , Orazi, Attilio , Cazzola, Mario , Döhner, Hartmut

Mayo Clinic

American Journal of Hematology | February 18, 2022 | Volume: 97 | Issue: 5 | Pages: 514-518

10.1002/ajh.26503 | PMID 35179244 Get It

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
Lenz, Heinz‐Josef , Breakstone, Rimini, Crysler, Oxana , Bolch, Emily, Niedzwiecki, Donna , Elsing, Alicia, Hurwitz, Herbert I. , Bekaii‐Saab, Tanios , Zemla, Tyler J, Niedzwiecki, Donna , Bekaii-Saab, Tanios S , Mettu, Niharika B , Ou, Fang‐Shu , Zemla, Tyler , Hálfdánarson, Þorvarður R. , Boland, Patrick M. , Wu, Christina , Nixon, Andrew B. , Fakih, Marwan

Mayo Clinic

JAMA Network Open | February 18, 2022 | Volume: 5 | Issue: 2 | Pages: e2149040

10.1001/jamanetworkopen.2021.49040 | PMID 35179586 Get It

Social risk factors predicting outcomes of cervical myelopathy surgery
Rethorn, Zachary D., Cook, Chad E., Park, Christine, Somers, Tamara, Mummaneni, Praveen V., Chan, Andrew K., Pennicooke, Brenton H., Bisson, Erica F., Asher, Anthony L., Buchholz, Avery L., Bydon, Mohamad, Alvi, Mohammed Ali, Coric, Domagoj, Foley, Kevin T., Fu, Kai-Ming, Knightly, John J., Meyer, Scott, Park, Paul, Potts, Eric A., Shaffrey, Christopher I., Shaffrey, Mark, Than, Khoi D., Tumialan, Luis, Turner, Jay D., Upadhyaya, Cheerag D., Wang, Michael Y., Gottfried, Oren, Park, Paul , Alvi, Mohammed Ali , Alvi, Mohammed Ali , Rethorn, Zachary D., Cook, Chad E., Park, Christine, Somers, Tamara, Mummaneni, Praveen V., Chan, Andrew K., Pennicooke, Brenton H., Bisson, Erica F., Asher, Anthony L., Buchholz, Avery L., Bydon, Mohamad, Alvi, Mohammed Ali, Coric, Domagoj, Foley, Kevin T., Fu, Kai-Ming, Knightly, John J., Meyer, Scott, Park, Paul, Potts, Eric A., Shaffrey, Christopher I., Shaffrey, Mark, Than, Khoi D., Tumialan, Luis, Turner, Jay D., Upadhyaya, Cheerag D., Wang, Michael Y., Gottfried, Oren, Turner, Jay D.

Mayo Clinic

Journal of Neurosurgery: Spine | February 18, 2022 | Volume: 37 | Issue: 1 | Pages: 41-48

10.3171/2021.12.spine21874 | PMID 35090132 Get It

OBJECTIVE Combinations of certain social risk factors of race, sex, education, socioeconomic status (SES), insurance, education, employment, and one’s housing situation have been associated with poorer pain and disability outcomes after lumbar spine surgery. To date, an exploration of such factors in patients with cervical spine surgery has not been conducted. The objective of the current work was to 1) define the social risk phenotypes of individuals who have undergone cervical spine surgery for myelopathy and 2) analyze their predictive capacity toward disability, pain, quality of life, and patient satisfaction–based outcomes. METHODS The Cervical Myelopathy Quality Outcomes Database was queried for the period from January 2016 to December 2018. Race/ethnicity, educational attainment, SES, insurance payer, and employment status were modeled into unique social phenotypes using latent class analyses. Proportions of social groups were analyzed for demonstrating a minimal clinically important difference (MCID) of 30% from baseline for disability, neck and arm pain, quality of life, and patient satisfaction at the 3-month and 1-year follow-ups. RESULTS A total of 730 individuals who had undergone cervical myelopathy surgery were included in the final cohort. Latent class analysis identified 2 subgroups: 1) high risk (non-White race and ethnicity, lower educational attainment, not working, poor insurance, and predominantly lower SES), n = 268, 36.7% (class 1); and 2) low risk (White, employed with good insurance, and higher education and SES), n = 462, 63.3% (class 2). For both 3-month and 1-year outcomes, the high-risk group (class 1) had decreased odds (all p < 0.05) of attaining an MCID score in disability, neck/arm pain, and health-related quality of life. Being in the low-risk group (class 2) resulted in an increased odds of attaining an MCID score in disability, neck/arm pain, and health-related quality of life. Neither group had increased or decreased odds of being satisfied with surgery. CONCLUSIONS Although 2 groups underwent similar surgical approaches, the social phenotype involving non-White race/ethnicity, poor insurance, lower SES, and poor employment did not meet MCIDs for a variety of outcome measures. This finding should prompt surgeons to proactively incorporate socially conscience care pathways within healthcare systems, as well as to optimize community-based resources to improve outcomes and personalize care for populations at social risk.
CDK7 inhibition augments the response against multidrug chemotherapy in pancreatic cancer
Zeng, Siyuan , Lan, Bin , Ren, Xiaofan, Zhang, Shuman , Schreyer, Daniel , Eckstein, Markus , Kutschick, Isabella, Pfeffer, Susanne, Grützmann, Robert , Zeng, Siyuan, Yang, Hai , Britzen‐Laurent, Nathalie , Dahl, Andreas , Mukhopadhyay, Debabrata , Chang, David K. , Bailey, Peter J. , Biankin, Andrew V. , Pilarsky, Christian , Eckstein, Markus

Mayo Clinic

No container title available | February 16, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1333955/v1 Get It

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal prognosis. Although combined treatment with gemcitabine and albumin-bound paclitaxel has improved the prognosis of PDAC, both intrinsic and acquired chemoresistance cloud the outcomes. Hence, there is an urgent need to explore new therapeutic targets and formulate innovative strategies for the more effective treatment of PDAC.Methods: We transduced pancreatic cancer cells with a protein kinase library, and transfected cells were selected by puromycin treatment, followed by continuous exposure to vehicle control or gemcitabine/paclitaxel chemotherapy for 21 days. Next-generation sequencing as well as MAGeCK-VISPR analysis were performed to the identify candidate genes. Finally, we used the CRISPR-Cas9 to knockout the target gene, confirming that it is a viable target for overcoming chemoresistance in vivo and in vitro.Results: We identified several cell cycle checkpoint kinases and DNA damage-related kinases as targets for overcoming chemoresistance. Among them, cyclin-dependent kinase 7 (CDK7) ranked highly in both screenings. We demonstrated that both gene knockout and pharmacological inhibition of CDK7 by THZ1 result in cell cycle arrest, apoptosis induction. Furthermore, THZ1 synergized with gemcitabine and paclitaxel in vitro and in vivo, resulting in enhanced antitumor effects.Conclusions: Our findings support the application of CRISPR-Cas9 screening in identifying novel therapeutic targets and provide new strategies for overcoming chemoresistance in pancreatic cancer.
Anti‐Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1
Ζεκερίδου, Αναστασία , Yang, Binxia , Lennon, Vanda A. , Guo, Yong , Lucchinetti, Claudia F. , McKeon, Andrew , Pittock, Sean J. , Zekeridou, Anastasia , Wu, Liang, McKeon, Andrew , Pittock, S J , Yang, Binxia , Wu, Liang Li , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | February 12, 2022 | Volume: 91 | Issue: 5 | Pages: 670-675

10.1002/ana.26320 | PMID 35150165 Get It

The antigen specificity of Anti‐Neuronal Nuclear Antibody‐type 3 (ANNA3)‐IgG is unknown. We identified Dachshund‐homolog 1 (DACH1) as the ANNA3 autoantigen and confirmed it by antigen‐specific assays, immunohistochemical colocalization and immune absorption experiments. Patients' median age was 63.5 years (range, 49–88); 67% were female. Neurological manifestations (information available for 30 patients) included one or more of neuropathy, 12; cognitive difficulties, 11; ataxia, 8; dysautonomia, 7. Evidence of a neoplasm was present in 27 of 30 (90%), most of neuroendocrine lineage. DACH1‐IgG is rare and represents a novel proposed biomarker of neurological autoimmunity and cancer. ANN NEUROL 2022;91:670–675
Treatment of nonsurgical refractory back pain with high-frequency spinal cord stimulation at 10 kHz: 12-month results of a pragmatic, multicenter, randomized controlled trial
Jameson, Jessica , Johnson, Curtis D., Kloster, Daniel, Calodney, Aaron , Kosek, Peter, Pilitsis, Julie G. , Bendel, Markus A. , Petersen, Erika , Cherry, Taissa, Lad, Shivanand P. , Goree, Johnathan , Lyons, Mark , Sack, Andrew , Bruce, Diana, Rubenstein, Frances, Province‐Azalde, Rose , Caraway, David , Bendel, Markus, Patel, Naresh P. , Kapural, Leonardo , Johnson, Curtis, Wu, Chengyuan , Yu, Cong , Sayed, Dawood

Mayo Clinic

Journal of Neurosurgery: Spine | February 11, 2022 | Volume: 37 | Issue: 2 | Pages: 188-199

10.3171/2021.12.spine211301 | PMID 35148512 Get It

OBJECTIVE Spinal cord stimulation (SCS) at 10 kHz (10-kHz SCS) is a safe and effective therapy for treatment of chronic low-back pain. However, it is unclear from existing evidence whether these findings can be generalized to patients with chronic back pain that is refractory to conventional medical management (CMM) and who have no history of spine surgery and are not acceptable candidates for spine surgery. The authors have termed this condition "nonsurgical refractory back pain" (NSRBP) and conducted a multicenter, randomized controlled trial to compare CMM with and without 10-kHz SCS in this population. METHODS Patients with NSRBP, as defined above and with a spine surgeon consultation required for confirmation, were randomized 1:1 to patients undergoing CMM with and without 10-kHz SCS. CMM included nonsurgical treatment for back pain, according to physicians’ best practices and clinical guidelines. Primary and secondary endpoints included the responder rate (≥ 50% pain relief), disability (Oswestry Disability Index [ODI]), global impression of change, quality of life (EQ-5D-5L), and change in daily opioid use and were analyzed 3 and 6 months after randomization. The protocol allowed for an optional crossover at 6 months for both arms, with observational follow-up over 12 months. RESULTS In total, 159 patients were randomized; 76 received CMM, and 69 (83.1%) of the 83 patients who were assigned to the 10-kHz SCS group received a permanent implant. At the 3-month follow-up, 80.9% of patients who received stimulation and 1.3% of those who received CMM were found to be study responders (primary outcome, ≥ 50% pain relief; p < 0.001). There was also a significant difference between the treatment groups in all secondary outcomes at 6 months (p < 0.001). In the 10-kHz SCS arm, outcomes were sustained, including a mean 10-cm visual analog scale score of 2.1 ± 2.3 and 2.1 ± 2.2 and mean ODI score of 24.1 ± 16.1 and 24.0 ± 17.0 at 6 and 12 months, respectively (p = 0.9). In the CMM arm, 74.7% (56/75) of patients met the criteria for crossover and received an implant. The crossover arm obtained a 78.2% responder rate 6 months postimplantation. Five serious adverse events occurred (procedure-related, of 125 total permanent implants), all of which resolved without sequelae. CONCLUSIONS The study results, which included follow-up over 12 months, provide important insights into the durability of 10-kHz SCS therapy with respect to chronic refractory back pain, physical function, quality of life, and opioid use, informing the current clinical practice for pain management in patients with NSRBP.
Hospital Frailty Risk Score and healthcare resource utilization after surgery for metastatic spinal column tumors
Elsamadicy, Aladine A. , Reeves, Benjamin C. , Pennington, Zach , Kolb, Luis, Laurans, Maxwell , Lo, Sheng-Fu Larry , Sciubba, Daniel M. , Pennington, Zach , Koo, Andrew B. , Yu, James B. , Goodwin, C. Rory , Shin, John H.

Mayo Clinic

Journal of Neurosurgery: Spine | February 11, 2022 | Volume: 37 | Issue: 2 | Pages: 241-251

10.3171/2022.1.spine21987 | PMID 35148505 Get It

OBJECTIVE The Hospital Frailty Risk Score (HFRS) was developed utilizing ICD-10 diagnostic codes to identify frailty and predict adverse outcomes in large national databases. While other studies have examined frailty in spine oncology, the HFRS has not been assessed in this patient population. The aim of this study was to examine the association of HFRS-defined frailty with complication rates, length of stay (LOS), total cost of hospital admission, and discharge disposition in patients undergoing spine surgery for metastatic spinal column tumors. METHODS A retrospective cohort study was performed using the years 2016 to 2019 of the National Inpatient Sample (NIS) database. All adult patients (≥ 18 years old) undergoing surgical intervention for metastatic spinal column tumors were identified using the ICD-10-CM diagnostic codes and Procedural Coding System. Patients were categorized into the following three cohorts based on their HFRS: low frailty (HFRS < 5), intermediate frailty (HFRS 5–15), and high frailty (HFRS > 15). Patient demographics, comorbidities, treatment modality, perioperative complications, LOS, discharge disposition, and total cost of hospital admission were assessed. A multivariate logistic regression analysis was used to identify independent predictors of prolonged LOS, nonroutine discharge, and increased cost. RESULTS Of the 11,480 patients identified, 7085 (61.7%) were found to have low frailty, 4160 (36.2%) had intermediate frailty, and 235 (2.0%) had high frailty according to HFRS criteria. On average, age increased along with progressively worsening frailty scores (p ≤ 0.001). The proportion of patients in each cohort who experienced ≥ 1 postoperative complication significantly increased along with increasing frailty (low frailty: 29.2%; intermediate frailty: 53.8%; high frailty: 76.6%; p < 0.001). In addition, the mean LOS (low frailty: 7.9 ± 5.0 days; intermediate frailty: 14.4 ± 13.4 days; high frailty: 24.1 ± 18.6 days; p < 0.001), rate of nonroutine discharge (low frailty: 40.4%; intermediate frailty: 60.6%; high frailty: 70.2%; p < 0.001), and mean total cost of hospital admission (low frailty: $48,603 ± $29,979; intermediate frailty: $65,271 ± $43,110; high frailty: $96,116 ± $60,815; p < 0.001) each increased along with progressing frailty. On multivariate regression analysis, intermediate and high frailty were each found to be significant predictors of both prolonged LOS (intermediate: OR 3.75 [95% CI 2.96–4.75], p < 0.001; high: OR 7.33 [95% CI 3.47–15.51]; p < 0.001) and nonroutine discharge (intermediate: OR 2.05 [95% CI 1.68–2.51], p < 0.001; high: OR 5.06 [95% CI 1.93–13.30], p = 0.001). CONCLUSIONS This study is the first to use the HFRS to assess the impact of frailty on perioperative outcomes in patients with metastatic bony spinal tumors. Among patients with metastatic bony spinal tumors, frailty assessed using the HFRS was associated with longer hospitalizations, more nonroutine discharges, and higher total hospital costs.